Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Aclaris Therapeutics

Status and phase: Terminated; Phase 2

Conditions: Psoriatic Arthritis

Treatments: Drug: ATI-450; Drug: Placebo Oral Tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT05511519

ATI-450-PsA-201

Details and patient eligibility

About

This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.

Full description

This is a Phase 2a, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.

Enrollment: 47 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of PsA with symptom onset at least 6 months before the Screening Visit and fulfilment of the Classification Criteria for PsA.

• Patient has moderate-to-severe PsA at Screening and Randomization Visits defined as

  • ≥3 tender joints (based on 68 joint counts) and
  • ≥3 swollen joints (based on 66 joint counts).

• Diagnosis of active plaque psoriasis or documented history of plaque psoriasis.

Exclusion criteria

• Any arthritis with onset before age 17 years, or current diagnosis of inflammatory joint disease other than PsA, or other immunological disease (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
• Patient has an uncontrolled non-immunoinflammatory disease that may place the patient at increased risk during the study or impact the interpretation of results, eg, cirrhosis, previous malignancy, previous venous thromboembolism.
• Any clinically significant laboratory abnormality that would affect interpretation of study data or safety of the patient's participation in the study, per judgment of the investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

47 participants in 2 patient groups, including a placebo group

ATI-450

Experimental group

Description:

ATI-450 50mg oral tablet BID

Treatment:

Drug: ATI-450

Placebo

Placebo Comparator group

Description:

Placebo oral tablet BID

Treatment:

Drug: Placebo Oral Tablet